TBCV 91
Alternative Names: TBCV-91Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator FibroGenesis
- Class Antineoplastics; Cancer vaccines; Fibroblast cell therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 21 Oct 2020 FibroGenesis has patents pending for fibroblast cell based personalised and universal cancer vaccines in USA (FibroGenesis' website, October 2020)
- 21 Oct 2020 Preclinical trials in Cancer in USA (Parenteral) before October 2020 (FibroGenesis' pipeline, October 2020)